Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
MarketBeat

ImmuCell Q1 Earnings Call Highlights

ImmuCell (NASDAQ:ICCC) reported a record first quarter of 2026, with management saying the company’s narrowed focus on its First Defense calf scours prevention portfolio helped drive its first-ever quarter above $10 million in product sales.

President and Chief Executive Officer Olivier te Boekhorst said the company is beginning to see results from strategic changes made in 2025, including a sharper focus on the calf scours market, leadership investments and manufacturing yield improvements.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.